Drug Trial Radar · NCT05932303
A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Oct 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
47
Actual
Start
Jul 12, 2023
Primary completion
Oct 23, 2023
Study completion Oct 23, 2023
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jul 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a study in healthy participants designed to assess the effect of multiple doses of itraconazole, gemfibrozil, or carbamazepine on the drug levels of a single-dose of BMS-986278.
Conditions
- Healthy Participants
Interventions
BMS-986278Drug
Specified dose on specified days
ItraconazoleDrug
Specified dose on specified days
GemfibrozilDrug
Specified dose on specified days
CarbamazepineDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax)Time frame: Up to 33 days
- Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration (AUC[0-T])Time frame: Up to 33 days
- Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC[INF])Time frame: Up to 33 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Local Institution - 0001
Québec, CA, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.